

Cover Story
By Jordan Williams and Matthew Bin Han Ong
When the Senate Committee on Appropriations marked up the fiscal 2019 spending bill, NIH came out ahead—$2 billion ahead.
In Brief
Clinical Roundup


Drugs & Targets
NCI Trials


NCI Trials for June
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month.
Trending Stories
- Vinay Prasad’s CV inaccurately claims past membership on the President’s Cancer Panel
- FDA’s second rejection of Replimune’s melanoma treatment stirs worry among oncologists, patients
“Patients are owed another review.” - Prasad’s “deceit,” plus, ODAC’s tough decision against biomarker-based progression assessment (for now)
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- CBER Director Vinay Prasad dared to “say no to drugs”
- Breakthrough Therapy designation, ASCO plenary, and NEJM publication notwithstanding, breast cancer drug camizestrant gets a No from ODAC















